Predictive tissue biomarkers for bevacizumab-containing therapy in metastatic colorectal cancer: an update

References

• Hamilton SR, Bosman FT, Boffetta P, et al. Carcinoma of the colon and rectum. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO Classification of Tumours of the Digestive System. International Agency for Research on Cancer (IARC), Lyon, France 2010;134-46
   Google Scholar
• The Cancer Genome Atlas. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487(7407):330-7
   PubMed Web of Science ®Google Scholar
• Jimenez CR, Knol JC, Meijer GA, Fijneman RJ. Proteomics of colorectal cancer: overview of discovery studies and identification of commonly identified cancer-associated proteins and candidate CRC serum markers. J Proteomics 2010;73(10):1873-95
   PubMed Web of Science ®Google Scholar
• Ferrarotto R, Hoff PM. Antiangiogenic drugs for colorectal cancer: exploring new possibilities. Clin Colorectal Cancer 2013;12(1):1-7
   PubMedGoogle Scholar
• Limaverde-Sousa G, Sternberg C, Ferreira CG. Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents. Cancer Treat Rev 2014;40(4):548-57
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Gerber H-P, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3(5):391-400
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42
   PubMed Web of Science ®Google Scholar
• Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008;8(8):579-91
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8(8):592-603
   PubMed Web of Science ®Google Scholar
• Patten SG, Adamcic U, Lacombe K, et al. VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment. BMC Cancer 2010;10(1):683
   PubMedGoogle Scholar
• Furlan D, Carnevali IW, Bernasconi B, et al. Hierarchical clustering analysis of pathologic and molecular data identifies prognostically and biologically distinct groups of colorectal carcinomas. Mod Pathol 2011;24(1):126-37
   PubMedGoogle Scholar
• Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 2013;108(3):479-85
   PubMed Web of Science ®Google Scholar
• Loges S, Schmidt T, Carmeliet P. Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer 2010;1(1):12-25
   PubMedGoogle Scholar
• Alsina M, Ruiz-Echarri M, Capdevila J, et al. Biomarkers for Therapies Directed at Angiogenesis. Curr Colorectal Cancer Rep 2010;6(3):133-43
   Google Scholar
• Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009;6(6):327-38
   PubMed Web of Science ®Google Scholar
• Gerger A, LaBonte M, Lenz H-J. Molecular predictors of response to antiangiogenesis therapies. Cancer J 2011;17(2):134-41
   PubMedGoogle Scholar
• Murukesh N, Dive C, Jayson GC. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer 2010;102(1):8-18
   PubMed Web of Science ®Google Scholar
• Otrock ZK, Hatoum HA, Musallam KM, et al. Is VEGF a predictive biomarker to anti-angiogenic therapy? Crit Rev Oncol Hematol 2011;79(2):103-11
   PubMedGoogle Scholar
• Hein M, Graver S. Tumor cell response to bevacizumab single agent therapy in vitro. Cancer Cell Int 2013;13(1):94
   PubMedGoogle Scholar
• Kara O, Duman BB, Kara B, et al. Analysis of PTEN, VEGF, HER2 and P53 Status in Determining Colorectal Cancer Benefit from Bevacizumab Therapy. Asian Pac J Cancer Prev 2012;13(12):6397-401
   PubMedGoogle Scholar
• Varey a HR, Rennel ES, Qiu Y, et al. VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. Br J Cancer 2008;98(8):1366-79
   PubMedGoogle Scholar
• Rennel ES, Varey a HR, Churchill a J, et al. VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo. Br J Cancer 2009;101(7):1183-93
   PubMedGoogle Scholar
• Jubb AM, Hurwitz HI, Bai W, et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006;24(2):217-27
   PubMed Web of Science ®Google Scholar
• Hong YS, Cho HJ, Kim SY, et al. Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer. BMC Cancer 2009;9:246
   PubMedGoogle Scholar
• Foernzler D, Delmar P, Kockx MM, et al. Tumor tissue based biomarker analysis in NO16966: A randomized phase III study of first-line bevacizumab in combination with oxaliplatin-based chemotherapy in patients with mCRC. In: Gastrointestinal Cancers Symposium. ASCO Orlando; 2010
   Google Scholar
• Pohl M, Werner N, Munding J, et al. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature. Z Gastroenterol 2011;49(10):1398-406
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kobunai T, Yamamoto Y, et al. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients. Dis Colon Rectum 2011;54(8):1026-35
   PubMedGoogle Scholar
• Bates DO, Catalano PJ, Symonds KE, et al. Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab. Clin Cancer Res 2012;18(22):6384-91
   PubMedGoogle Scholar
• Bates DO, Mavrou A, Qiu Y, et al. Detection of VEGF-A(xxx)b isoforms in human tissues. PLoS One 2013;8(7):e68399
   PubMed Web of Science ®Google Scholar
• Weickhardt AJ, Williams D, Lee C, et al. Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study. In: Gastrointestinal (Colorectal) Cancer: Colorectal Cancer Symposium. ASCO Chicago; 2011
   Google Scholar
• Duong T, Koopman P, Francois M. Tumor lymphangiogenesis as a potential therapeutic target. J Oncol 2012;2012(204946):1-23
   Google Scholar
• Gomes FG, Nedel F, Alves AM, et al. Tumor angiogenesis and lymphangiogenesis: tumor/endothelial crosstalk and cellular/microenvironmental signaling mechanisms. Life Sci 2013;92(2):101-7
   PubMed Web of Science ®Google Scholar
• Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009;21(2):154-65
   PubMed Web of Science ®Google Scholar
• Shibuya M. Vascular endothelial growth factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: a Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes Cancer 2011;2(12):1097-105
   PubMedGoogle Scholar
• Tchaikovski V, Fellbrich G, Waltenberger J. The molecular basis of VEGFR-1 signal transduction pathways in primary human monocytes. Arterioscler Thromb Vasc Biol 2008;28(2):322-8
   PubMed Web of Science ®Google Scholar
• Schwartz JD, Rowinsky EK, Youssoufian H, et al. Vascular endothelial growth factor receptor-1 in human cancer: concise review and rationale for development of IMC-18F1 (Human antibody targeting vascular endothelial growth factor receptor-1). Cancer 2010;116(4 Suppl):1027-32
   PubMedGoogle Scholar
• Yao J, Wu X, Zhuang G, et al. Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc Natl Acad Sci USA 2011;108(28):11590-5
   PubMed Web of Science ®Google Scholar
• Roybal JD, Zang Y, Ahn Y-H, et al. miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1. Mol Cancer Res 2011;9(1):25-35
   PubMed Web of Science ®Google Scholar
• Lambrechts D, Lenz H-J, de Haas S, et al. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 2013;31(9):1219-30
   PubMed Web of Science ®Google Scholar
• Smith NR, Baker D, James NH, et al. Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin Cancer Res 2010;16(14):3548-61
   PubMed Web of Science ®Google Scholar
• Xu L, Duda DG, di Tomaso E, et al. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res 2009;69(20):7905-10
   PubMed Web of Science ®Google Scholar
• Sitohy B, Nagy JA, Jaminet S-CS, Dvorak HF. Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy. Cancer Res 2011;71(22):7021-8
   PubMedGoogle Scholar
• Fakhrejahani E, Toi M. Tumor angiogenesis: pericytes and maturation are not to be ignored. J Oncol 2012;2012:261750-1-10
   PubMedGoogle Scholar
• Helfrich I, Scheffrahn I, Bartling S, et al. Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med 2010;207(3):491-503
   PubMed Web of Science ®Google Scholar
• Shojaei F, Ferrara N. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Drug Resist Updat 2008;11(6):219-30
   PubMedGoogle Scholar
• Kärpänen T. Lymphatic vessels in health and disease: Role of the VEGF-C/VEGFR-3 pathway and the transcription factor FOXC2. PhD Thesis, University of Helsinki, Helsinki
   Google Scholar
• Yildiz R, Coskun U, Baglan T, et al. The Relation between Endoglin (CD105), Thrombospondin-1 and VEGFR-3 and Treatment Results in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combination Therapy. In: Colorectal Cancer Symposium. ESMO Milan; 2010
   Google Scholar
• Chaudhary B, Khaled YS, Ammori BJ, Elkord E. Neuropilin 1: function and therapeutic potential in cancer. Cancer Immunol Immunother 2014;63(2):81-99
   PubMed Web of Science ®Google Scholar
• Galdiero MR, Bonavita E, Barajon I, et al. Tumor associated macrophages and neutrophils in cancer. Immunobiology 2013;218(11):1402-10
   PubMed Web of Science ®Google Scholar
• Gaengel K, Genové G, Armulik A, Betsholtz C. Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler Thromb Vasc Biol 2009;29(5):630-8
   PubMed Web of Science ®Google Scholar
• Zhang L, Nishihara H, Kano MR. Pericyte-coverage of human tumor vasculature and nanoparticle permeability. Biol Pharm Bull 2012;35(5):761-6
   PubMed Web of Science ®Google Scholar
• Franco M, Roswall P, Cortez E, et al. Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. Blood 2011;118(10):2906-17
   PubMed Web of Science ®Google Scholar
• Goede V, Coutelle O, Neuneier J, et al. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer 2010;103(9):1407-14
   PubMed Web of Science ®Google Scholar
• Noonan S, Martin P, Biniecka M, et al. Correlation of high levels of immature blood vessels in colorectal tumors with longer survival following bevacizumab treatment. In: Tumor Biology: Molecular Targets Symposium. ASCO Chicago; 2011
   Google Scholar
• Smith NR, Baker D, Farren M, et al. Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy. Clin Cancer Res 2013;19(24):6943-56
   PubMed Web of Science ®Google Scholar
• Qin D, Trenkwalder T, Lee S, et al. Early vessel destabilization mediated by Angiopoietin-2 and subsequent vessel maturation via Angiopoietin-1 induce functional neovasculature after ischemia. PLoS One 2013;8(4):e61831
   Google Scholar
• Kienast Y, Klein C, Scheuer W, et al. Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy. Clin Cancer Res 2013;19(24):6730-40
   PubMed Web of Science ®Google Scholar
• Willett CG, Boucher Y, Duda DG, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005;23(31):8136-9
   PubMed Web of Science ®Google Scholar
• Sundaram P, Hultine S, Smith LM, et al. p53-responsive miR-194 inhibits thrombospondin-1 and promotes angiogenesis in colon cancers. Cancer Res 2011;71(24):7490-501
   PubMed Web of Science ®Google Scholar
• Zhao H-Y, Ooyama A, Yamamoto M, et al. Molecular basis for the induction of an angiogenesis inhibitor, thrombospondin-1, by 5-fluorouracil. Cancer Res 2008;68(17):7035-41
   PubMedGoogle Scholar
• Gil M, Seshadri M, Komorowski MP, et al. Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases. Proc Natl Acad Sci USA 2013;110(14):E1291-300
   PubMed Web of Science ®Google Scholar
• Fox SB. Assessing tumor angiogenesis in histological samples. Methods Mol Biol 2009;467:55-78
   PubMedGoogle Scholar
• De Bruyne S, Van Damme N, Smeets P, et al. Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases. Br J Cancer 2012;106(12):1926-33
   PubMedGoogle Scholar
• Zhang L, Jiang W, Zhang Y, et al. Predictive values of intratumoral microvascular density (MVD) in the patients (pts) with advanced NSCLC and metastatic colorectal cancer (mCRC) receiving chemotherapy plus bevacizumab. In: Developmental Therapeutics: Molecular Therapeutics: Antiangiogenic or Antimetastatic Agents Symposium. ASCO Orlando; 2009
   Google Scholar
• Hansen TF, Christensen RD, Andersen RF, et al. MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial. Br J Cancer 2013;109(5):1243-51
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473(7347):298-307
   PubMed Web of Science ®Google Scholar
• Barlow KD, Sanders AM, Soker S, et al. Pericytes on the tumor vasculature: Jekyll or Hyde? Cancer Microenviron 2013;6(1):1-17
   PubMedGoogle Scholar
• Guijarro-Muñoz I, Sánchez A, Martínez-Martínez E, et al. Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab. Med Oncol 2013;30(2):572
   PubMedGoogle Scholar
• McIntyre A, Patiar S, Wigfield S, et al. Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy. Clin Cancer Res 2012;18(11):3100-11
   PubMed Web of Science ®Google Scholar
• Rohrberg KS, Pappot H, Lassen U, et al. Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab. Cancer Biol Ther 2011;11(8):732-9
   PubMed Web of Science ®Google Scholar
• Li Q, Wang D, Li J, Chen P. Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas. BMC Cancer 2011;11(1):277
   PubMedGoogle Scholar
• Pity IS, Arif SH, Hadji DA. Angiogenesis, p53 and Bcl 2 in Colorectal Carcinoma. Int J Adv Res Technol 2013;2(3):1-8
   Google Scholar
• Ince WL, Jubb AM, Holden SN, et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005;97(13):981-9
   PubMedGoogle Scholar
• Selvakumaran M, Amaravadi RK, Vasilevskaya IA, O’Dwyer PJ. Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic therapy. Clin Cancer Res 2013;19(11):2995-3007
   PubMed Web of Science ®Google Scholar
• Klionsky DJ, Abdalla FC, Abeliovich H, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012;8(4):445-544
   PubMed Web of Science ®Google Scholar
• Espina V, Mueller C, Edmiston K, et al. Tissue is alive: new technologies are needed to address the problems of protein biomarker pre-analytical variability. Proteomics Clin Appl 2009;3(8):874-82
   PubMedGoogle Scholar
• Bai Y, Tolles J, Cheng H, et al. Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables. Lab Invest 2011;91(8):1253-61
   PubMed Web of Science ®Google Scholar
• Siddiqui S, Rimm DL. Pre-analytic variables and phospho-specific antibodies: the Achilles heel of immunohistochemistry. Breast Cancer Res 2010;12(6):113
   PubMedGoogle Scholar
• Ghiringhelli F, Bichard D, Limat S, et al. Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection. Ann Surg Oncol 2014;21(5):1632-40
   PubMedGoogle Scholar
• Croci DO, Cerliani JP, Dalotto-Moreno T, et al. Glycosylation-Dependent Lectin-Receptor Interactions Preserve Angiogenesis in Anti-VEGF Refractory Tumors. Cell 2014;156(4):744-58
   PubMed Web of Science ®Google Scholar
• Pang L, Xu J, Shu C, et al. Characterization and cancer cell targeted imaging properties of human antivascular endothelial growth factor monoclonal antibody conjugated CdTe/ZnS quantum dots. Luminescence 2014;29(8):1177-82
   PubMedGoogle Scholar
• Dolloff NG, Ma X, Dicker DT, et al. Spectral imaging-based methods for quantifying autophagy and apoptosis. Cancer Biol Ther 2011;12(4):349-56
   PubMed Web of Science ®Google Scholar